Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 42Carboplatin 24Cyclophosphamide 20Paclitaxel 19Nivolumab 17Cisplatin 15fludarabine 14Gemcitabine 12aldesleukin 10Docetaxel 10Bevacizumab 9Magnetic Resonance Spectroscopy 8Trastuzumab 7Specimen Handling 7Drug Therapy 7Pemetrexed 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Fluorouracil 6Cetuximab 6Blood Specimen Collection 6sargramostim 5pegfilgrastim 5avelumab 5Topotecan 5Taxes 5Irinotecan 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × ciforadenant × Thoracic × Clear all
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡